NOS1AP is a novel molecular target and critical factor in TDP-43 pathology

NYGC ALS Consortium

Research output: Contribution to journalArticlepeer-review

Abstract

Many lines of evidence have highlighted the role played by heterogeneous nuclear ribonucleoproteins in amyotrophic lateral sclerosis. In this study, we have aimed to identify transcripts co-regulated by TAR DNA-binding protein 43 kDa and highly conserved heterogeneous nuclear ribonucleoproteins which have been previously shown to regulate TAR DNA-binding protein 43 kDa toxicity (deleted in azoospermia-associated protein 1, heterogeneous nuclear ribonucleoprotein -Q, -D, -K and -U). Using the transcriptome analyses, we have uncovered that Nitric Oxide Synthase 1 Adaptor Protein mRNA is a direct TAR DNA-binding protein 43 kDa target, and in flies, its modulation alone can rescue TAR DNA-binding protein 43 kDa pathology. In primary mouse cortical neurons, we show that TAR DNA-binding protein 43 kDa mediated downregulation of Nitric Oxide Synthase 1 Adaptor Protein expression strongly affects the NMDA-receptor signalling pathway. In human patients, the downregulation of Nitric Oxide Synthase 1 Adaptor Protein mRNA strongly correlates with TAR DNA-binding protein 43 kDa proteinopathy as measured by cryptic Stathmin-2 and Unc-13 homolog A cryptic exon inclusion. Overall, our results demonstrate that Nitric Oxide Synthase 1 Adaptor Protein may represent a novel disease-relevant gene, potentially suitable for the development of new therapeutic strategies.

Original languageEnglish
JournalBrain Communications
Volume4
Issue number5
DOIs
StatePublished - 2022

Funding

FundersFunder number
Fondazione Italiana di Ricerca
Temerty Foundation Canada

    Keywords

    • ALS
    • CAPON/NOS1AP
    • RNA stability
    • TDP-43
    • hnRNPs

    Fingerprint

    Dive into the research topics of 'NOS1AP is a novel molecular target and critical factor in TDP-43 pathology'. Together they form a unique fingerprint.

    Cite this